Table 1.
General characteristics of polymyxin prescriptions over the study period before and after antimicrobial stewardship program (ASP) implementation.
| Variables | Pre-ASP Implementation (n) |
2016–2017 (n) |
2017–2018 (n) |
2018–2019 (n) |
2019–2020 (n) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | PB | Total | C | PB | Total | C | PB | Total | C | PB | Total | C | PB | Total | |
| 738 | 34 | 772 | 315 | 95 | 410 | 358 | 128 | 486 | 314 | 62 | 376 | 370 | 28 | 398 | |
| Age | |||||||||||||||
| Median (IQR) |
55 (30) | 50.50 (39) | 54 (32) | 55 (32) | 55 (24) | 55 (30) | 54 (27) | 51.50 (22) | 53 (26) | 56 (35) | 54 (18) | 56 (30) | 48 (59) | 61 (7) | 50 (58) |
| Above 80 years, n (%) | 18 | 0 | 18 (2%) | 9 | 1 | 10 (2%) | 2 | 0 | 2 (0.4%) | 10 | 1 | 11 (3%) | 10 | 1 | 11 (3%) |
| Sex | |||||||||||||||
| Male | 491 | 21 | 512 (67%) | 230 | 65 | 295 (72%) | 227 | 81 | 308 (63%) | 214 | 39 | 253 (67%) | 246 | 21 | 267 (67%) |
| Focus of Infection | |||||||||||||||
| Pneumonia | 289 | 17 | 306 (40%) | 87 | 31 | 118 (29%) | 105 | 41 | 146 (30%) | 137 | 29 | 166 (44%) | 272 | 35 | 307 (77%) |
| UTI | 186 | 7 | 193 (25%) | 88 | 11 | 99 (24%) | 103 | 15 | 118 (24%) | 83 | 10 | 93 (25%) | 97 | 3 | 100 (25%) |
| Bacteremia | 182 | 8 | 190 (25%) | 92 | 46 | 138 (34%) | 146 | 63 | 209 (43%) | 92 | 20 | 112 (30%) | 127 | 4 | 131 (33%) |
| Skin and soft tissue infection | 75 | 5 | 80 (10%) | 36 | 3 | 39 (10%) | 34 | 10 | 44 (9%) | 39 | 7 | 46 (12%) | 49 | 2 | 51 (13%) |
| Abdominal | 7 | 0 | 7 (1%) | 8 | 3 | 11 (3%) | 16 | 7 | 23 (5%) | 16 | 8 | 24 (6%) | 35 | 4 | 39 (10%) |
| CNS | 4 | 4 | 8 (1%) | 2 | 1 | 3 (1%) | 12 | 4 | 16 (3%) | 5 | 2 | 7 (2%) | 39 | 0 | 39 (10%) |
| Others* | 17 | 0 | 17 (2%) | 0 | 0 | 0 | 52 | 15 | 67 (14%) | 54 | 26 | 80 (21%) | 140 | 19 | 159 (40%) |
| Culture Sent | |||||||||||||||
| Culture sent prior to antibiotics | 649 | 31 | 680 (88%) | 307 | 89 | 396 (96%) | 246 | 90 | 336 (69%) | 292 | 57 | 349 (93%) | 344 | 26 | 370 (93%) |
| Culture sent after antibiotics | 86 | 2 | 88 (11%) | 8 | 6 | 14 (3%) | 145 | 56 | 201 (41%) | 17 | 4 | 21 (5%) | 27 | 5 | 32 (8%) |
| Culture not sent | 3 | 1 | 4 (0.5%) | 1 | 0 | 1 (0.24%) | 3 | 1 | 4 (1%) | 2 | 1 | 3 (0.7%) | 7 | 0 | 7 (2%) |
| Appropriateness | 29 | 0 | 29 (4%) | 73 | 30 | 103 (25%) | 241 | 91 | 332 (68%) | 253 | 48 | 301 (79%) | 325 | 22 | 347 (83%) |
| Outcome | |||||||||||||||
| Mortality | 201 | 10 | 211 (27%) | 91 | 20 | 111 (27%) | 80 | 43 | 123 (25%) | 52 | 14 | 66 (17%) | 69 | 12 | 81 (20%) |
The percentages depict the proportion of the specified variable among the total of patients prescribed with polymyxins in the particular year given. Others* includes febrile neutropenia, otitis media, infective endocarditis, endophthalmitis, septic arthritis, discitis, sepsis with unknown source and septic shock. C = colistin, PB = polymyxin B.